{"id":"polmacoxib","rwe":[{"pmid":"41834674","year":"2026","title":"Development and Validation of Reverse Phase High-Performance Liquid Chromatographic Method Enabling Simultaneous Estimation of Polmacoxib and its Process-Related Impurities: Exploring Degradation Pathways and Elucidating Degradant Structures via LC-MS/MS and NMR Spectroscopy.","finding":"","journal":"Journal of chromatographic science","studyType":"Clinical Study"},{"pmid":"41403234","year":"2025","title":"Bioanalytical method development for polmacoxib in rat plasma using LC-MS/MS and Its preclinical pharmacokinetic evaluation.","finding":"","journal":"Bioanalysis","studyType":"Clinical Study"},{"pmid":"41257112","year":"2025","title":"Evaluation of Polmacoxib 2 mg for the Management of Hip and Knee Osteoarthritis: A Prospective, Single-Arm, Multicenter, Open-Label Study.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"41100334","year":"2025","title":"Review of Safety and Efficacy of Polmacoxib: A Novel Dual Inhibitor of Cyclo-oxygenase 2 and Carbonic Anhydrase in Osteoarthritis and Acute Painful Conditions.","finding":"","journal":"The Journal of the Association of Physicians of India","studyType":"Clinical Study"},{"pmid":"40021487","year":"2025","title":"Polypharmacology of carbonic anhydrase inhibitors and activators.","finding":"","journal":"Expert opinion on pharmacotherapy","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Prostaglandin G/H synthase 2","category":"target"},{"label":"PTGS2","category":"gene"},{"label":"PTGS1","category":"gene"},{"label":"M01AH07","category":"atc"},{"label":"Active","category":"status"},{"label":"Osteoarthritis","category":"indication"},{"label":"CrystalGenomics","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"CrystalGenomics","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=POLMACOXIB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:55:18.421640+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:55:24.871586+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=POLMACOXIB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:55:25.161258+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Carbonic anhydrase I inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:55:26.288182+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL166863/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:55:25.874898+00:00"}},"allNames":"acelex","offLabel":[],"synonyms":["polmacoxib","acelex","CG-100649","CG100649"],"timeline":[{"date":"2015-02-05","type":"positive","source":"DrugCentral","milestone":"Korean Food and Drug Administration (KFDA) approval (CrystalGenomics)"}],"approvals":[{"date":"2015-02-05","orphan":false,"company":"CrystalGenomics","regulator":"Korean Food and Drug Administration (KFDA)"}],"brandName":"Acelex","ecosystem":[{"indication":"Osteoarthritis","otherDrugs":[{"name":"aceclofenac","slug":"aceclofenac","company":""},{"name":"acetylsalicylic acid","slug":"acetylsalicylic-acid","company":"Endo Pharms"},{"name":"celecoxib","slug":"celecoxib","company":"Gd Searle"},{"name":"choline magnesium trisalicylate","slug":"choline-magnesium-trisalicylate","company":""}],"globalPrevalence":655000000}],"mechanism":{"target":"Prostaglandin G/H synthase 2","targets":[{"gene":"PTGS2","source":"DrugCentral","target":"Prostaglandin G/H synthase 2","protein":"Prostaglandin G/H synthase 2"},{"gene":"PTGS1","source":"DrugCentral","target":"Prostaglandin G/H synthase 1","protein":"Prostaglandin G/H synthase 1"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Acelex specifically targets the COX-2 enzyme, a subtype of prostaglandin G/H synthase 2, to selectively inhibit the production of prostaglandins and reduce inflammation without affecting other bodily functions."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5240","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=POLMACOXIB","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=POLMACOXIB","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:26:31.355873","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:55:27.489544+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"celecoxib","drugSlug":"celecoxib","fdaApproval":"1998-12-31","patentExpiry":"May 27, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"rofecoxib","drugSlug":"rofecoxib","fdaApproval":"1999-05-20","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"valdecoxib","drugSlug":"valdecoxib","fdaApproval":"2001-11-16","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"polmacoxib","indications":{"approved":[{"name":"Osteoarthritis","source":"DrugCentral","snomedId":396275006,"regulator":"FDA","usPrevalence":null,"globalPrevalence":655000000,"prevalenceMethod":"curated","prevalenceSource":"Arthritis Res Ther, 2023 (PMID:36991481)"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"celecoxib","brandName":"celecoxib","genericName":"celecoxib","approvalYear":"1998","relationship":"same-class"},{"drugId":"rofecoxib","brandName":"rofecoxib","genericName":"rofecoxib","approvalYear":"1999","relationship":"same-class"},{"drugId":"valdecoxib","brandName":"valdecoxib","genericName":"valdecoxib","approvalYear":"2001","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06590714","phase":"NA","title":"Perioperative Polmacoxib Reduce Opioid Consumption for Post Operative Pain After Rotator Cuff Tear.","status":"RECRUITING","sponsor":"Eulji University Hospital","startDate":"2024-08-23","conditions":["Rotator Cuff Tear"],"enrollment":150,"completionDate":"2025-08-31"},{"nctId":"NCT01154764","phase":"PHASE1","title":"Trial for Studying Pharmacokinetic Effects of Ketoconazole on CG100649","status":"COMPLETED","sponsor":"CrystalGenomics, Inc.","startDate":"2009-10","conditions":["Healthy"],"enrollment":28,"completionDate":"2010-12"},{"nctId":"NCT01765296","phase":"PHASE3","title":"Phase III Study of CG100649 in Osteoarthritis Patients","status":"COMPLETED","sponsor":"CrystalGenomics, Inc.","startDate":"2013-03","conditions":["Localized Primary Osteoarthritis of Hip","Localized Primary Osteoarthritis of Knee"],"enrollment":362,"completionDate":"2014-04"},{"nctId":"NCT01341405","phase":"PHASE2","title":"Study of CG100649 Versus Celecoxib in Osteoarthritis Patients","status":"COMPLETED","sponsor":"CrystalGenomics, Inc.","startDate":"2011-04","conditions":["Osteoarthritis"],"enrollment":125,"completionDate":"2012-01"},{"nctId":"NCT05370716","phase":"PHASE1","title":"Drug-Drug Interaction Study of \"CG-651\" in Healthy Volunteer","status":"COMPLETED","sponsor":"CrystalGenomics, Inc.","startDate":"2019-11-11","conditions":["Healthy"],"enrollment":47,"completionDate":"2020-05-19"},{"nctId":"NCT03775629","phase":"PHASE1","title":"Drug-Drug Interaction Study of \"CG100650\" in Healthy Volunteers","status":"COMPLETED","sponsor":"CrystalGenomics, Inc.","startDate":"2018-12-01","conditions":["Healthy"],"enrollment":41,"completionDate":"2019-04-10"},{"nctId":"NCT01154790","phase":"PHASE1","title":"Phase I Study on Multiple Oral Dosing of CG100649","status":"COMPLETED","sponsor":"CrystalGenomics, Inc.","startDate":"2010-06","conditions":["Healthy"],"enrollment":120,"completionDate":"2011-01"},{"nctId":"NCT00780325","phase":"PHASE1","title":"Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2008-10","conditions":["Healthy Volunteers"],"enrollment":26,"completionDate":"2013-07"},{"nctId":"NCT00530452","phase":"PHASE2","title":"Phase II Study of CG100649 for Primary Osteoarthritis in Male Subjects","status":"UNKNOWN","sponsor":"CrystalGenomics, Inc.","startDate":"2007-10","conditions":["Osteoarthritis, Knee","Osteoarthritis, Hip"],"enrollment":240,"completionDate":"2008-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"018797","UNII":"IJ34D6YPAO","INN_ID":"9898","UMLSCUI":"C4519118","chemblId":"CHEMBL166863","ChEMBL_ID":"CHEMBL166863","KEGG_DRUG":"D10656","DRUGBANK_ID":"DB12399","PDB_CHEM_ID":" 949","PUBCHEM_CID":"9841854","IUPHAR_LIGAND_ID":"8316","MESH_SUPPLEMENTAL_RECORD_UI":"C000599293"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"CrystalGenomics","relationship":"Original Developer"}],"publicationCount":17,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"M01AH07","allCodes":["M01AH07"]},"biosimilarFilings":[],"originalDeveloper":"CrystalGenomics","recentPublications":[{"date":"2026 Feb 13","pmid":"41834674","title":"Development and Validation of Reverse Phase High-Performance Liquid Chromatographic Method Enabling Simultaneous Estimation of Polmacoxib and its Process-Related Impurities: Exploring Degradation Pathways and Elucidating Degradant Structures via LC-MS/MS and NMR Spectroscopy.","journal":"Journal of chromatographic science"},{"date":"2025 Dec","pmid":"41403234","title":"Bioanalytical method development for polmacoxib in rat plasma using LC-MS/MS and Its preclinical pharmacokinetic evaluation.","journal":"Bioanalysis"},{"date":"2025 Oct","pmid":"41257112","title":"Evaluation of Polmacoxib 2 mg for the Management of Hip and Knee Osteoarthritis: A Prospective, Single-Arm, Multicenter, Open-Label Study.","journal":"Cureus"},{"date":"2025 Oct","pmid":"41100334","title":"Review of Safety and Efficacy of Polmacoxib: A Novel Dual Inhibitor of Cyclo-oxygenase 2 and Carbonic Anhydrase in Osteoarthritis and Acute Painful Conditions.","journal":"The Journal of the Association of Physicians of India"},{"date":"2025 Apr","pmid":"40021487","title":"Polypharmacology of carbonic anhydrase inhibitors and activators.","journal":"Expert opinion on pharmacotherapy"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"CrystalGenomics","companyId":"crystalgenomics","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"Korean Food and Drug Administration (KFDA)","status":"approved","approval_date":"2015-02-05T00:00:00.000Z","mah":"CrystalGenomics","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:55:27.489544+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}